bakersson Thursday, 05/16/19 04:54:37 PM Re: None Post # of 31586 News out. Australian Partnership. On May 16, 2019, MannKind Corporation (“MannKind”) issued a press release announcing MannKind’s entry into an exclusive marketing and distribution agreement with the AMSL Diabetes division of Australasian Medical & Scientific Ltd. (“AMSL Diabetes”) for the commercialization of Afrezza® (insulin human) Inhalation Powder in Australia. Under the terms of the agreement, AMSL Diabetes is responsible for obtaining regulatory and reimbursement approvals to distribute Afrezza in Australia. AMSL Diabetes is also responsible for sales, marketing, and customer support and distribution activities. MannKind is responsible for the supply and manufacturing of Afrezza.